Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston blog main
boston top stories
3
×
life sciences
national blog main
national top stories
new york blog main
san diego blog main
san francisco blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
medicare
national
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego top stories
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alex azar
alirocumab
american patients first
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bill &
biosimilars
bluebird bio
boston
center for medicare and medicaid services
What
drug
3
×
long
3
×
awaited
details
house
lower
plan
prices
afternoon
ago
anathema
anticipated
biotechs
blueprint
considering
cost
cut
data
democrat
diseases
drugs
dyne
early
elements
expected
experimental
eyes
genetic
having
humans
ipo
ipos
leaked
look
meant
medicines
monday
muscle
night
pledges
Language
unset
Current search:
biotech
×
long
×
" boston top stories "
×
drug
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
6 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details